VK 2809

Drug Profile

VK 2809

Alternative Names: MB-07811; VK-2809

Latest Information Update: 06 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Metabasis Therapeutics
  • Developer University of Amsterdam; Viking Therapeutics
  • Class Antihyperlipidaemics; Obesity therapies; Organophosphorus compounds; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia; Non-alcoholic fatty liver disease
  • Preclinical Adrenoleucodystrophy; Glycogen storage disease type I; Non-alcoholic steatohepatitis

Most Recent Events

  • 05 Jun 2018 Viking Therapeutics completes enrolment in its phase II trial for Hypercholesterolaemia and non-alcoholic fatty liver disease (NAFLD) (NCT02927184)
  • 09 May 2018 Viking Therapeutics plans a phase I proof-of concept trial for Glycogen storage disease type Ia in second quarter of 2018
  • 24 Oct 2017 Preclinical data in Non-alcoholic steatohepatitis presented at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top